1. Home
  2. MP vs GH Comparison

MP vs GH Comparison

Compare MP & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$62.94

Market Cap

12.2B

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$102.27

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
GH
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.2B
14.1B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
MP
GH
Price
$62.94
$102.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
21
Target Price
$70.92
$79.19
AVG Volume (30 Days)
10.4M
2.4M
Earning Date
11-06-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$232,742,000.00
$902,569,000.00
Revenue This Year
$37.00
$34.72
Revenue Next Year
$145.29
$26.46
P/E Ratio
N/A
N/A
Revenue Growth
26.44
30.38
52 Week Low
$15.56
$29.91
52 Week High
$100.25
$112.43

Technical Indicators

Market Signals
Indicator
MP
GH
Relative Strength Index (RSI) 50.83 56.90
Support Level $57.24 $103.36
Resistance Level $61.66 $109.59
Average True Range (ATR) 3.73 5.54
MACD 0.85 -1.11
Stochastic Oscillator 68.76 42.83

Price Performance

Historical Comparison
MP
GH

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: